ArticleFrontiers in aging neuroscience2026
Association of the Naples prognostic score with Parkinson disease risk: a prospective cohort study.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Naples prognostic score (NPS), derived from routine inflammatory and nutritional biomarkers, reflects systemic immune-metabolic status. Its prospective association with Parkinson disease (PD) risk has not been well established. Methods: We analyzed 317,035 UK Biobank participants recruited in 2006-2010 who were free of PD and malignancy at baseline and had complete NPS component data. NPS was derived from serum albumin, total cholesterol, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio. Incident PD through 31 December 2022 was identified using a validated algorithm. Associations were examined using Cox proportional hazards models with multivariable adjustment. Results: Over a median follow-up of 13.94 years, 2,298 participants (0.72%) developed PD. Higher NPS was significantly associated with increased PD risk. After multivariable adjustment, each 1-point increase in NPS corresponded to a 13% higher risk (Model 2 adjusted HR = 1.13, 95% CI: 1.07-1.19, Conclusion: In this large prospective cohort, higher NPS was independently associated with increased PD risk. These findings support the potential role of integrated inflammatory-nutritional status in PD development and suggest that NPS may serve as a readily available marker for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.